Novo Nordisk finds its footing again

Novo Nordisk (NVO) has received a 'buy' upgrade from Berenberg, setting a DKK425 target price, following a significant two-thirds share price collapse from its mid-2024 peak. This renewed optimism stems from Wegovy's regaining momentum via a CVS Caremark deal and label expansions, a deeper pipeline including oral Wegovy and CagriSema with above-consensus sales forecasts, and a new CEO's DKK8 billion cost-cutting program. With expectations reset and the stock trading at a discount (14.5x 2026 earnings), the company is positioned to prove its long-term potential beyond current flagship products, despite ongoing risks like price erosion and impending Medicare cuts.

Analysis

Following a significant share price correction that saw the stock fall by two-thirds from its mid-2024 peak, Novo Nordisk is showing signs of a turnaround, underscored by a Berenberg upgrade to 'buy' with a DKK425 price target. The core of this renewed optimism is a reset in valuation and expectations; the stock now trades at approximately 14.5 times 2026 earnings, a 35% discount to its 10-year average. Key commercial momentum is being driven by Wegovy, which has secured an exclusive reimbursement deal with CVS Caremark, displacing rival Eli Lilly's Zepbound on that formulary and leading to an observed uptick in prescription trends since July. This is further supported by label expansions for fatty liver disease and an anticipated approval for heart failure by year-end. Beyond the near term, the pipeline appears more robust than previously perceived, with an oral version of Wegovy expected in 2026 and the combination therapy CagriSema, for which some sales forecasts are 25% above consensus by 2030. A new CEO is also implementing an DKK8 billion cost-saving initiative to fuel R&D and commercial reinvestment. However, risks persist, including accelerating price erosion in the U.S. obesity market, impending Medicare price cuts for semaglutide from 2027, and significant product concentration around Wegovy and Ozempic.

Key Decisions for Investors

• Given the stock's discounted valuation at 14.5x 2026 earnings and the potential 20% upside to the new DKK425 price target, investors may consider the current price an attractive entry point.
• Investors should closely monitor prescription data for Wegovy versus Zepbound to validate the market share recapture thesis stemming from the CVS Caremark formulary change.
• Key catalysts to watch include the expected heart failure label expansion for Wegovy before year-end and the new CEO's strategic update, both of which could drive a further re-rating of the stock.
• It is prudent to remain aware of medium-term risks, specifically accelerating price erosion from new oral competitors and the impact of Medicare price negotiations on semaglutide starting in 2027.